CTLA4 and melanoma: The purpose of this study is to examine, at a population level, the extent to which use of anti-PD-1/CTLA-4 combination immunotherapy is associated with an increased incidence of adverse neurologic events in melanoma patients in comparison to monotherapy PD-1 inhibitor regimens.